The Current Ratio as of September 2024 (TTM) for Inhibrx, Inc. (INBX) is 6.20

According to Inhibrx, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.20. This represents a change of -2.46% compared to the average of 6.35 of the last 4 quarters.

Inhibrx, Inc. (INBX) Historical Current Ratio (quarterly & annually)

How has INBX Current Ratio performed in the past?

The mean historical Current Ratio of Inhibrx, Inc. over the last ten years is 4.07. The current 6.20 Current Ratio has changed 15.15% with respect to the historical average. Over the past ten years (40 quarters), INBX's Current Ratio was at its highest in in the December 2022 quarter at 10.17. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Inhibrx, Inc. (INBX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Inhibrx, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibrx, Inc. (INBX) Average Current Ratio

How has INBX Current Ratio performed in the past?

The current Current Ratio of Inhibrx, Inc. (INBX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Inhibrx, Inc. (INBX) Current Ratio vs. Peers

How is INBX’s Current Ratio compared to its peers?

Inhibrx, Inc.’s Current Ratio is less than Crinetics Pharmaceuticals, Inc. (16.09), less than Merus N.V. (9.97), less than Lyell Immunopharma, Inc. (16.19), less than Kronos Bio, Inc. (8.49), greater than Opthea Limited (2.94), less than Mineralys Therapeutics, Inc. (11.20), less than Eliem Therapeutics, Inc. (60.41), greater than Anebulo Pharmaceuticals, Inc. (5.32), less than Merrimack Pharmaceuticals, Inc. (10.78), less than Celcuity Inc. (14.95), less than Enliven Therapeutics, Inc. (14.39), less than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), less than Stoke Therapeutics, Inc. (6.67), less than Protagonist Therapeutics, Inc. (13.73), less than DICE Therapeutics, Inc. (25.88), less than Larimar Therapeutics, Inc. (10.93), less than Viridian Therapeutics, Inc. (15.82),

Build a custom stock screener for Inhibrx, Inc. (INBX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibrx, Inc. (INBX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibrx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.